Takeda teams with Sanford-Burnham on cardio R&D; Medicines Co. touts early promise for sedative;

@FierceBiotech: ASCO 15: The top 10 setbacks, advances and head scratchers. Editor's corner | Follow @FierceBiotech

@JohnCFierce: $IMGN shares up 14% on positive early data for ovarian cancer ADC. Release | Follow @JohnCFierce

> Takeda has partnered up with the Sanford-Burnham Medical Research Institute to study how certain regulatory proteins relate to heart failure. Under a two-year collaboration, the pair aims to discover small-molecule treatments that strengthen the heart. More

> ABP-700, a new short-acting sedative from the Medicines Company ($MDCO), came through in a Phase I trial. News

> Puma Biotechnology's ($PBYI) breast cancer drug helped women already treated with Herceptin stay free of invasive disease in a Phase III trial, but the drug only narrowly bested placebo. More

Medical Device News

@FierceMedDev: ICYMI: DOJ slaps Olympus with a subpoena over dirty duodenoscopes. Article | Follow @FierceMedDev

@VarunSaxena2: FMD exclusive (got insider tip): Zimmer to cut some staff as it barrels toward merger with Biomet. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Otsuka faces the music for generic Abilify, loses battle with FDA. Article | Follow @EmilyWFierce

> Molecular Dx: Invitae drops prices as NIH starts 1,000-patient, molecular abnormalities cancer study. More

> Startup Arsenal Medical and its spinoff raise $26.5M to develop novel foam, nanofiber and bioresorbable products. Article

Pharma News

@FiercePharma: ICYMI: Adding Opdivo to Yervoy ups melanoma treatment efficacy--but it ups rate of serious side effects, too. Report | Follow @FiercePharma

@CarlyHFierce: UPDATED w/Genentech comment: Roche's Gazyva doubles remission time for non-Hodgkin lymphoma patients. Story | Follow @CarlyHFierce

> Top oncologist joins chorus of pricing critics in high-profile ASCO speech. More

> UCB reportedly gets bids for Kremers Urban unit from Cipla and Lupin. Article

Animal Health News

> Tech makers market health wearables to dog owners. Item

> Groundbreaking held for the new $1.2B NABF animal health facility in Kansas. More

> Bayer CEO Dekkers looking 'with interest' at animal-health additions. Report

> K-State researchers build avian-flu protection into existing poultry vaccine. Article

> Novozymes enters booming market for poultry probiotics. Story

Biotech IT News

> CRISPR Therapeutics starts search for a bioinformatics chief. More

> Bioinformatics leads UCSD team to ovarian cancer biomarkers. Story

> AstraZeneca's Definiens rolls out biomarker data service. Item

> Artificial intelligence tops Google VC's list of high-potential life sci techs. Article

> UT Southwestern snags $5.6M grant to boost bioinformatics operation. Report

Pharma Marketing News

> Stars of cancer meeting set to crack top 10 cancer sales by 2020. Article

> Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA. Report

> Novartis rolls out 'life hacks' for MS patients with new Live Like You campaign. Article

> ASCO must-reads: Pfizer's Ibrance; BMS, Novartis melanoma meds; J&J's Imbruvica and more. More

> Abbott takes Pedialyte on the festival circuit as grown-up hangover remedy. Story

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.